CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2022 | $36,000 | -5.3% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $38,000 | -70.3% | 600 | -64.7% | 0.00% | -66.7% |
| Q4 2021 | $128,000 | -52.2% | 1,700 | -29.2% | 0.00% | -50.0% |
| Q3 2021 | $268,000 | -28.0% | 2,400 | +4.3% | 0.01% | -25.0% |
| Q2 2021 | $372,000 | +291.6% | 2,300 | +196.8% | 0.01% | +300.0% |
| Q1 2021 | $95,000 | +55.7% | 775 | +93.8% | 0.00% | 0.0% |
| Q4 2020 | $61,000 | +74.3% | 400 | -50.0% | 0.00% | +100.0% |
| Q3 2018 | $35,000 | -25.5% | 800 | 0.0% | 0.00% | -50.0% |
| Q2 2018 | $47,000 | – | 800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |